Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia
The availability of novel targeted agents has revolutionized the management of chronic lymphocytic leukemia (CLL). Both B-cell lymphoma 2 (BCL2) and Bruton tyrosine kinase (BTK) inhibitors are highly effective agents for CLL treatment. Several clinical trials have demonstrated the efficacy and safet...
Salvato in:
| Autori principali: | , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Wolters Kluwer Medknow Publications
2023-10-01
|
| Serie: | Hematology/Oncology and Stem Cell Therapy |
| Soggetti: | |
| Accesso online: | https://journals.lww.com/10.56875/2589-0646.1039 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|